Competition Law and Bioeconomy Platform Concentration Issues

1. Introduction

The bioeconomy encompasses economic activity based on biological resources, biotechnology, genetic information, biological production systems, agricultural biotechnology, synthetic biology, bio-based chemicals, pharmaceuticals, genomics, precision agriculture, biofuels, biomaterials and related digital infrastructure.

A bioeconomy platform is a particularly important modern structure. It may connect:

• biotechnology researchers and laboratories;
• farmers and agricultural-input suppliers;
• seed developers and trait owners;
• genomic-data providers and diagnostic companies;
• laboratories and sequencing platforms;
• pharmaceutical developers and healthcare providers;
• suppliers of biological inputs and downstream manufacturers;
• users of biological databases, algorithms and AI tools.

Concentration becomes a competition-law issue when one undertaking acquires or controls several strategically important layers of such an ecosystem. The concern is not simply the firm's percentage market share. Data, intellectual property, network effects, interoperability, switching costs, R&D pipelines and control over essential technological inputs can all reinforce market power.

The most relevant legal theories are therefore horizontal concentration, vertical foreclosure, conglomerate effects, nascent-competition theories, innovation competition and platform/ecosystem effects.

2. Meaning of Bioeconomy Platform Concentration

Bioeconomy concentration may arise through:

A. Horizontal mergers

Two competing biotechnology or biological-input platforms combine.

Example: two genomic-data platforms or two agricultural digital platforms merge.

Potential effects include:

• elimination of a direct competitor;
• increased concentration of biological datasets;
• reduction in R&D rivalry;
• higher licensing prices;
• reduced product variety;
• reduction in innovation incentives.

B. Vertical integration

A platform controlling an upstream biological input acquires a downstream platform.

For example:

sequencing technology → genomic data → diagnostic platform → clinical application.

If the upstream undertaking controls an indispensable technology, acquisition of a downstream application may create an incentive to disadvantage competing downstream developers.

The Illumina/GRAIL litigation is particularly important in understanding this theory. The FTC alleged that Illumina controlled a critical sequencing input used by competing multi-cancer early-detection developers and could therefore disadvantage rivals of GRAIL after acquisition.

C. Conglomerate/ecosystem concentration

A company may acquire businesses operating at several adjacent levels:

seed + traits + pesticides + farm data + algorithms + digital agriculture marketplace.

The individual markets may appear competitive when examined separately, while the combined ecosystem can produce substantial strategic advantages.

D. Data concentration

Bioeconomy platforms can accumulate:

• genomic data;
• agricultural-field data;
• phenotypic data;
• clinical datasets;
• biological research data;
• proprietary algorithms;
• customer and laboratory data.

A merger can therefore produce data-driven entry barriers even where traditional physical assets are not particularly scarce.

3. Principal Competition-Law Framework

A. Merger control

The primary legal question is whether the transaction is likely to substantially lessen or impede effective competition.

Depending on jurisdiction, authorities examine:

1. relevant product market;
2. geographic market;
3. market shares;
4. closeness of competition;
5. barriers to entry;
6. innovation competition;
7. access to data;
8. control over intellectual property;
9. vertical relationships;
10. network effects;
11. switching costs;
12. potential competition;
13. efficiencies and remedies.

4. Why Traditional Market-Share Analysis May Be Insufficient

Bioeconomy platforms often operate in rapidly developing markets.

A platform might currently possess only a modest share but control:

• a critical dataset;
• a patented technology;
• a sequencing standard;
• an important biological database;
• a distribution ecosystem;
• an important agricultural-data network;
• a high-value R&D pipeline.

Consequently, future competitive significance may matter more than current revenue.

This is illustrated particularly clearly by Illumina/Pacific Biosciences, where the FTC alleged that PacBio represented a nascent competitive threat to Illumina's position in next-generation DNA sequencing. The transaction was abandoned after the FTC challenged it.

5. Network Effects

Bioeconomy platforms can exhibit strong network effects.

For example:

More laboratories → more data → better algorithms → more users → more data → stronger platform.

Similarly:

More farmers → more agricultural data → better predictive models → more farmers.

A merger involving two platforms may therefore increase the strength of the combined network disproportionately.

Competition authorities may consequently consider whether concentration will:

• reinforce network effects;
• disadvantage smaller platforms;
• increase switching costs;
• reduce interoperability;
• make multi-homing more difficult;
• permit discriminatory access.

6. Data as a Competitive Asset

Data can constitute an important source of competitive advantage.

Consider a precision-agriculture platform possessing:

• soil data;
• weather information;
• crop-performance data;
• pesticide-response data;
• satellite imagery;
• farmer purchasing information.

Combining this dataset with a major seed or pesticide business can create a powerful feedback loop.

The competition concern is not necessarily that the company "owns data" in an abstract sense. Rather, the question is whether the combined data asset creates an unreplicable competitive advantage.

Relevant questions include:

• Can rivals obtain equivalent data?
• Can farmers easily transfer their data?
• Are data interoperable?
• Are APIs available?
• Is data portability technically feasible?
• Does the merged undertaking obtain commercially sensitive information about rivals?
• Can the platform use data generated by customers to compete against them?

7. Intellectual Property and Platform Concentration

Bioeconomy markets frequently depend upon:

• patents;
• plant breeders' rights;
• trade secrets;
• proprietary databases;
• biological material;
• research licences;
• technical standards.

A concentration may therefore create a combination of IP power + data power + platform power.

Competition authorities must distinguish legitimate intellectual-property protection from conduct that uses IP strategically to exclude competitors.

8. Innovation Competition

Innovation is particularly significant because bioeconomy markets often evolve before products reach commercialisation.

Competition may occur between:

• existing products;
• pipeline products;
• research projects;
• alternative technologies;
• competing scientific approaches.

Thus, a merger can harm competition even where the parties have relatively limited present-day sales.

The European Commission's analysis in Dow/DuPont expressly recognised innovation competition in crop protection, including competition involving products still in the discovery stage.

9. Vertical Foreclosure

Vertical foreclosure can occur where a platform controls an upstream input needed by downstream competitors.

The basic structure is:

Upstream platform → critical biological technology → downstream applications

After acquiring one downstream application, the upstream company may theoretically have incentives to:

• increase input prices;
• reduce quality;
• delay access;
• restrict interoperability;
• limit licences;
• discriminate between customers;
• provide preferential treatment to its own downstream subsidiary.

The authority normally needs to consider both ability and incentive, together with likely competitive effects.

10. Six Major Case Laws

Case 1: Illumina, Inc. v. Federal Trade Commission / Illumina–GRAIL

Jurisdiction: United States
Area: Genomics, sequencing, cancer diagnostics, vertical concentration

Illumina was a major supplier of next-generation sequencing technology, while GRAIL was developing a multi-cancer early-detection test relying upon sequencing technology.

The FTC challenged the acquisition on the theory that Illumina's control over an important upstream input could allow it to disadvantage competing developers of cancer-detection tests.

The FTC ultimately ordered divestiture. The Fifth Circuit later held that there was substantial evidence supporting the Commission's determination but remanded on the treatment of part of Illumina's rebuttal evidence. Illumina subsequently announced that it would divest GRAIL.

Principle

The case demonstrates the importance of:

• vertical foreclosure;
• control over critical technological inputs;
• innovation competition;
• nascent markets;
• access to infrastructure;
• interoperability between technological platforms.

Bioeconomy significance

It is one of the clearest examples of how concentration involving genomic infrastructure and biological applications can create competition concerns even where the merging parties operate at different levels of the value chain.

Case 2: Illumina/Pacific Biosciences

Jurisdiction: United States
Area: DNA sequencing

The FTC challenged Illumina's proposed acquisition of PacBio.

The theory was that PacBio represented an important nascent competitive threat in next-generation DNA sequencing. The FTC alleged that eliminating PacBio could allow Illumina to maintain its existing position and reduce future competition.

The transaction was abandoned in January 2020.

Principle

A merger need not eliminate a large current competitor to create competition concerns.

An undertaking may be competitively important because of its:

• technology;
• R&D pipeline;
• potential to disrupt the market;
• ability to constrain an incumbent in the future.

Bioeconomy significance

This is especially relevant to:

• genomics;
• synthetic biology;
• biological AI;
• sequencing;
• laboratory technology;
• bioinformatics.

Case 3: Bayer/Monsanto

Jurisdiction: European Union
Area: Seeds, pesticides and digital agriculture

The European Commission examined Bayer's acquisition of Monsanto across numerous agricultural markets.

The transaction raised concerns relating to seeds, pesticides and digital agriculture.

Importantly, the remedies included transfer of Bayer's digital-agriculture assets, including relevant:

• intellectual property;
• software;
• source code;
• data;
• algorithms;
• employees;
• customer contracts;
• datasets.

The Commission stated that the remedies were intended to preserve competition and innovation in digital agriculture.

Principle

Competition analysis can extend beyond traditional physical products to the digital layer of a biological ecosystem.

Bioeconomy significance

This case is extremely important because it illustrates how:

seeds + pesticides + biological traits + agricultural data + algorithms

can form an integrated competitive ecosystem.

Case 4: Dow/DuPont

Jurisdiction: European Union
Area: Crop protection and agricultural biotechnology

The Commission examined the merger between Dow and DuPont.

The investigation considered both existing product competition and innovation competition.

The Commission identified concerns involving herbicides, insecticides, fungicides and other products and also examined pipeline and discovery-stage innovation.

Remedies included substantial divestments, including assets associated with crop-protection R&D.

Principle

Merger analysis can protect competition that has not yet crystallised into commercial sales.

Bioeconomy significance

This is particularly relevant to:

• biological pesticides;
• gene-edited crops;
• agricultural biotechnology;
• bio-based chemicals;
• synthetic-biology platforms;
• R&D-intensive bioeconomy markets.

Case 5: ChemChina/Syngenta

Jurisdiction: European Union
Area: Agricultural chemicals and crop protection

The European Commission examined ChemChina's acquisition of Syngenta.

Concerns arose because concentration would have reduced competition across various crop-protection markets, including fungicides, herbicides, insecticides and seed-treatment products.

The transaction was approved subject to extensive commitments and divestitures designed to preserve competition.

Principle

A concentration involving a major biological/agricultural-input platform may require analysis across numerous crop and product segments rather than treating agriculture as one unified market.

Bioeconomy significance

It demonstrates the importance of:

• product-specific markets;
• geographic differences;
• portfolio effects;
• input substitution;
• innovation;
• divestiture remedies.

Case 6: Roche/Spark Therapeutics

Jurisdiction: United States
Area: Gene therapy and biotechnology

The FTC investigated Roche's proposed acquisition of Spark Therapeutics.

The investigation examined potential competition in hemophilia-A therapies, including Spark's developmental gene-therapy programme and Roche's existing treatment.

After an extensive investigation, the FTC closed the investigation, concluding that the evidence did not establish that Roche would have the incentive to delay or terminate Spark's developmental effort or alter its incentives concerning the existing therapy.

Principle

Not every acquisition involving a powerful incumbent and a biotechnology developer is necessarily anticompetitive.

Authorities must examine the actual evidence concerning:

• pipeline products;
• innovation incentives;
• substitutability;
• commercial incentives;
• likely post-merger conduct.

Bioeconomy significance

This provides an important counterexample to automatic intervention and demonstrates the importance of evidence-based merger analysis.

11. Comparative Case-Law Table

12. Platform Self-Preferencing

A concentrated bioeconomy platform may operate both as:

1. infrastructure provider; and
2. competitor using that infrastructure.

For example:

Genomic-data platform → independent biotech companies
and simultaneously → platform's own diagnostic business.

This creates potential self-preferencing concerns.

Possible practices include:

• ranking affiliated products first;
• preferential access to biological datasets;
• faster API access for affiliated businesses;
• discriminatory licensing;
• preferential technical support;
• restrictions on rival data portability.

The competition question is whether such conduct excludes equally efficient competitors or otherwise harms competition.

13. Interoperability Concerns

Bioeconomy platforms often need to communicate with other systems.

Examples include:

• laboratory information systems;
• genomic databases;
• agricultural machinery;
• farm-management software;
• diagnostic systems;
• pharmaceutical research platforms.

A concentrated platform may have an incentive to make interoperability difficult.

Potential concerns include:

Technical restrictions

• incompatible APIs;
• proprietary formats;
• restricted software development kits.

Contractual restrictions

• exclusivity;
• anti-interoperability clauses;
• restrictions on data export.

Commercial restrictions

• discriminatory pricing;
• bundled services;
• loyalty discounts.

14. Switching Costs

Switching costs can be particularly high in biotechnology.

A customer may have to:

• redesign experiments;
• validate a new platform;
• transfer historical data;
• reconfigure laboratory systems;
• repeat regulatory validation;
• retrain personnel;
• reproduce clinical or agricultural trials.

Consequently, even technically substitutable platforms may not constitute effective competitive substitutes.

This is one reason why competition authorities may examine lock-in rather than merely asking whether another technology exists.

15. Access to Biological Data

A platform merger may create concerns if the merged entity obtains access to commercially sensitive information belonging to competitors.

For example, a sequencing platform might learn:

• which tests competitors are developing;
• their research volumes;
• technical requirements;
• customer identities;
• development timelines;
• performance data.

The merged firm could potentially use such information strategically.

Competition analysis therefore increasingly needs to distinguish:

data necessary to provide the platform service

from

competitively sensitive data capable of strengthening downstream market power.

16. Bundling and Tying

A bioeconomy platform can bundle several products:

sequencing + cloud storage + genomic analytics + laboratory software.

Or:

seeds + pesticides + farm-management software + data subscription.

Bundling may generate legitimate efficiencies, but competition concerns may arise where a firm with substantial market power uses one product to reinforce another market.

Relevant questions include:

1. Are the products commercially distinct?
2. Does the undertaking possess market power in the tying product?
3. Are customers effectively compelled to purchase the bundle?
4. Can rivals compete on equal terms?
5. Are there objective efficiencies?
6. Does bundling increase barriers to entry?

17. Exclusive Dealing

Bioeconomy platforms may also use:

• exclusive research agreements;
• exclusive seed-distribution arrangements;
• exclusive data licences;
• exclusive laboratory arrangements;
• exclusive genomic-analysis contracts.

Where the platform already possesses substantial market power, widespread exclusivity may prevent rivals from obtaining the scale necessary to compete.

18. Killer-Acquisition Concerns

A major bioeconomy platform may acquire a small biotechnology company precisely when that company begins developing a disruptive technology.

The target may have:

• minimal revenue;
• substantial scientific potential;
• valuable patents;
• promising R&D;
• unique datasets.

Traditional turnover-based merger thresholds may fail to capture such transactions.

Therefore, competition authorities may examine:

• transaction value;
• R&D pipeline;
• patent portfolio;
• innovation potential;
• customer adoption;
• technological substitutability.

Illumina/PacBio illustrates why a seemingly smaller competitor can have substantial competitive significance.

19. Nascent Competition

Nascent competition is particularly important in the bioeconomy because technological trajectories are uncertain.

A small company may become a major competitor through:

• gene editing;
• synthetic biology;
• precision fermentation;
• AI-assisted drug discovery;
• genomic diagnostics;
• biological carbon capture;
• microbial production.

The relevant question is therefore not merely:

"How much does the target currently sell?"

but also:

"What competitive constraint could the target impose if allowed to develop independently?"

20. Ecosystem Lock-In

A concentrated bioeconomy platform can produce a cycle:

Data → better algorithms → more users → more data → stronger algorithms → higher switching costs → greater market power

This is particularly relevant for digital agriculture.

A platform that controls:

• farm data;
• seed recommendations;
• crop analytics;
• pesticide recommendations;
• machinery integration;
• marketplace access

may become difficult for farmers to leave even where alternative individual services exist.

21. Efficiencies

Concentration can also generate legitimate efficiencies.

Possible efficiencies include:

• lower R&D costs;
• faster biological discovery;
• integrated datasets;
• improved disease detection;
• better agricultural forecasting;
• reduced duplication of research;
• faster clinical development;
• improved supply chains.

Competition authorities therefore should not assume that every integration is harmful.

The important distinction is between:

verifiable, merger-specific efficiencies

and

claimed efficiencies that could be achieved without eliminating competition.

22. Possible Competition Remedies

Authorities may use structural or behavioural remedies.

Structural remedies

• divestment of business units;
• divestment of datasets;
• sale of R&D pipelines;
• transfer of patents;
• transfer of algorithms;
• transfer of digital platforms;
• licensing of technology to an independent competitor.

Behavioural remedies

• non-discriminatory access;
• API access;
• interoperability commitments;
• data portability;
• firewalls;
• non-exclusivity;
• licensing commitments;
• prohibition of self-preferencing.

The Bayer/Monsanto matter demonstrates how remedies can encompass not merely physical businesses but also digital agriculture assets, data, algorithms and source code.

23. Competition Risks Specific to Bioeconomy Platforms

The major risks can be summarised as follows:

1. Data concentration

One platform accumulates datasets unavailable to rivals.

2. IP concentration

Patents and biological know-how become concentrated.

3. R&D concentration

Fewer independent research programmes remain.

4. Input foreclosure

Competitors lose access to essential biological or technological inputs.

5. Customer foreclosure

The platform controls access to an important group of downstream customers.

6. Network effects

Large platforms become progressively harder to challenge.

7. Interoperability restrictions

Rivals cannot integrate effectively.

8. Switching costs

Customers are effectively locked into the ecosystem.

9. Self-preferencing

The platform favours its own biological products.

10. Nascent-competitor acquisition

Potential disruptive competitors disappear through acquisition.

24. Indian Competition-Law Perspective

In India, these issues would principally be examined under the Competition Act, 2002, particularly:

• Section 5 — combinations;
• Section 6 — regulation of combinations;
• Section 19 — inquiry into combinations and anti-competitive conduct;
• Section 3 — anti-competitive agreements;
• Section 4 — abuse of dominant position.

For bioeconomy platforms, the Competition Commission of India could potentially examine factors such as:

• market share;
• economic power;
• size and importance of competitors;
• entry barriers;
• consumer dependence;
• vertical integration;
• control of technology;
• access to data;
• innovation;
• network effects;
• substitutability;
• countervailing buyer power.

The relevant market would require particular care. A single broad market such as "biotechnology" may conceal substantial competitive differences between:

• genomic sequencing;
• genomic analytics;
• agricultural biotechnology;
• digital agriculture;
• biological inputs;
• gene therapy;
• bioinformatics;
• biological research tools.

25. A Useful Analytical Model

For an examination or research problem, the following sequence is useful:

Bioeconomy Platform

↓

Identify ecosystem layers

↓

Define relevant product/service markets

↓

Identify data, IP and technological assets

↓

Measure existing concentration

↓

Identify network effects and switching costs

↓

Analyse horizontal overlap

↓

Analyse vertical foreclosure

↓

Analyse conglomerate/ecosystem effects

↓

Assess innovation and nascent competition

↓

Examine efficiencies

↓

Consider structural/behavioural remedies

↓

Determine likely effect on competition

26. Key Legal Lessons from the Six Cases

Illumina/GRAIL

Shows the importance of critical-input foreclosure and vertical innovation concerns.

Illumina/PacBio

Shows that nascent competition can justify merger scrutiny even where the target's current commercial position is comparatively limited.

Bayer/Monsanto

Shows that digital agriculture assets, algorithms and datasets can be central competitive assets in a biological ecosystem.

Dow/DuPont

Shows that competition law can protect innovation pipelines, not merely existing products.

ChemChina/Syngenta

Shows that bioeconomy concentration can require detailed analysis across numerous product and geographic markets.

Roche/Spark

Shows that authorities must establish actual evidence of likely competitive harm, rather than assuming that every acquisition of a biotechnology innovator is anticompetitive.

27. Conclusion

Bioeconomy platform concentration is fundamentally an ecosystem competition problem. Traditional concentration measures remain important, but they do not fully capture the competitive significance of biological data, intellectual property, R&D pipelines, technological standards, network effects and platform dependency.

The most important competition-law questions are therefore:

1. Who controls the critical biological or technological input?
2. Who controls the data?
3. Who controls access to customers?
4. Can rivals interoperate with the platform?
5. Can customers switch?
6. Does the transaction eliminate a nascent innovator?
7. Does vertical integration create foreclosure incentives?
8. Does the transaction reduce innovation competition?
9. Can claimed efficiencies be independently verified?
10. Can remedies preserve an independent competitive constraint?